Company news

Amgen Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Patients With Solid Tumors At ESMO 2019

September 26, 2019

Amgen Announces Positive Results From Two Phase 3 BLINCYTO® (blinatumomab) Studies In Pediatric Patients With Relapsed Acute Lymphoblastic Leukemia

September 23, 2019

Amgen Announces New Clinical Data Evaluating Novel Investigational KRAS(G12C) Inhibitor In Larger Patient Group At WCLC 2019

September 7, 2019

Amgen To Webcast Investor Call At IASLC 2019 World Conference on Lung Cancer

September 3, 2019

Amgen To Acquire Otezla® For $13.4 Billion In Cash, Or Approximately $11.2 Billion Net Of Anticipated Future Cash Tax Benefits

August 25, 2019

Amgen And Allergan Announce Positive Top-Line Results From Comparative Clinical Study Of ABP 798, Biosimilar Candidate To Rituxan® (Rituximab)

August 21, 2019

Amgen Wins Patent Case On Enbrel® (etanercept)

August 8, 2019

Amgen Announces 2019 Third Quarter Dividend

August 1, 2019

Amgen And Allergan's MVASI(TM) (bevacizumab-awwb) And KANJINTI(TM) (trastuzumab-anns) Now Available In The United States

July 17, 2019

Amgen Announces The Outcome Of The Recommended Public Cash Offer To The Shareholders Of Nuevolution, Declares The Offer Unconditional And Completes The Offer

July 7, 2019

Amgen And MBC BioLabs Announce Winners Of The Amgen Golden Ticket

June 24, 2019

Amgen And The Institute For Protein Design (IPD) At University Of Washington Announce Unique Strategic Research Partnership

June 18, 2019

Amgen Announces BLINCYTO® (blinatumomab) Five-Year Overall Survival Data At EHA 2019

June 14, 2019

FDA Approves Amgen And Allergan's KANJINTI(TM) (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)

June 12, 2019

Amgen Publishes Offer Document With Respect To The Recommended Public Cash Offer To The Shareholders Of Nuevolution

June 11, 2019

Amgen To Present At The Goldman Sachs 40th Annual Global Healthcare Conference

June 6, 2019

Amgen Announces First Clinical Data Evaluating Novel Investigational KRASG12C Inhibitor AMG 510 At ASCO 2019

June 2, 2019

Amgen To Webcast Investor Meeting At 55th Annual Meeting Of The American Society Of Clinical Oncology (ASCO)

May 28, 2019

Amgen Joins With Community Oncology Networks For New Research Collaboration

May 27, 2019

Amgen announces a recommended public cash offer to the shareholders of Nuevolution

May 20, 2019

Amgen To Highlight Extensive Long-Term Safety And Efficacy Data Of Aimovig® (erenumab-aooe) Across The Spectrum Of Migraine At AAN Annual Meeting

May 1, 2019

Amgen Announces Webcast of 2019 First Quarter Financial Results

April 24, 2019

Amgen Foundation Launches Amgen Biotech Experience In Tampa, Florida

April 16, 2019

← Newer news releases

Calls

The 5 newest of 29 calls. Every call is listed under its year.

Decks

The 5 newest of 28 decks. Every deck is listed under its year.